Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1

作者：

Escudier, Bernard ^{[1
]}

Joly, Florence ^{[2
]}

Soria, Jean-Charles ^{[3
]}

机构：

[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[2] Ctr Francois Baclesse, F-14076 Caen 05, France

[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷

关键词：

renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;

D O I：

10.1684/bdc.2011.1444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta

引用

页码：S3 / S6

页数：4

共 50 条

[21] Metastasis Targeted Therapies in Renal Cell Cancer
Narter, K. Fehmi
Ozveren, Bora
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 26 - 32
[22] Value of targeted therapies for renal cell cancer
Merseburger, A. S.
Kuczyk, M. A.
UROLOGE, 2008, 47 (10): : 1303 - +
[23] Targeted therapies in metastatic renal cancer in 2009
Bastien, Laurence
Culine, Stephane
Paule, Bernard
Ledbai, Souhil
Patard, Jean Jacques
de la Taille, Alexandre
BJU INTERNATIONAL, 2009, 103 (10) : 1334 - 1342
[24] Targeted Therapies in Advanced Renal Cell Cancer
Karaaslan, Sinan
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (03): : 210 - 213
[25] Dermatologic toxicities associated with targeted therapies: nursing implications associated with targeted therapies
Nematollahi, M.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S58 - S58
[26] Targeted Therapies in Colorectal Cancer: Complications and Management
Sundermeyer, Mark L.
Lessin, Stuart R.
Meropol, Neal J.
CURRENT COLORECTAL CANCER REPORTS, 2006, 2 (03) : 125 - 133
[27] Targeted therapies in the management of metastatic bladder cancer
Fassan, Matteo
Trabulsi, Edouard J.
Gomella, Leonard G.
Baffa, Raffaele
BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 393 - 406
[28] The management of cancer in the elderly: Targeted therapies in oncology
Agostara B.
Carruba G.
Usset A.
Immunity & Ageing, 5 (1)
[29] Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors
Cuyle, Pieter-Jan
Prenen, Hans
ANNALS OF GASTROENTEROLOGY, 2018, 31 (02): : 140 - 150
[30] Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
McFarlane, Thomas
Rehman, Noor
Wang, Katie
Lee, Jenny
Carter, Caitlin
ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (03) : 1296 - +

← 1 2 3 4 5 →